FDA Proposes Stricter Rules for Broadcast Drug Advertisements

The FDA is considering a new rule that would remove the "adequate provision" option for direct-to-consumer prescription drug ads on broadcast media. This change would mandate that such advertisements include a comprehensive summary of all side effects and contraindications. This move could effectively make broadcast drug ads too long and costly, potentially leading to a de-facto ban on them.